#Primary Immunodeficiency Diseases Market Research Report: Forecast up to 2023 | Explore Tumblr posts and blogs

healthy-insights · 7 years ago

Text

Primary Immunodeficiency Diseases Market Research Report: Forecast up to 2023

This report on the primary immunodeficiency diseases (PIDD) market studies the current as well as future prospects of the market. The stakeholders of this report include pharmaceuticals companies, diagnostic kits providers, distributors, care providers and insurance companies (payers) and other intermediaries engaged in PIDD as well as new entrants that are planning to enter in this segment. This report comprises an elaborate executive summary with a market snapshot providing overall information of various segments and sub-segments considered in the study scope. The executive summary also provides overall information and data analysis of the PIDD market with respect to the leading market segments based on Disease, Test, Treatment and Geography. The market revenue in terms of USD million for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all segments and sub-segments considered under the scope of study, considering 2014 as the base year. Pipeline analysis (qualitative) for Phase I, II candidates whereas a detailed quantitative aspect (US$ Mn) for III drugs are illustrated in the market overview chapter.

The report analyzed the PIDD market from four prominent segments: by Disease, by Test, by Treatment and by Geography. In terms of market by disease the overall market is segmented into three broad categories: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder. The antibody deficiency market is further analyzed and estimated for Agammaglobulinaemia, Common Variable Immune Deficiency, Selective IgA Deficiency, IgG Subclass Deficiency and Others. Whereas, cellular immunodeficiency market is sub-segmented into Ataxia Telangiectasia, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome, DiGeorge Syndrome and Others. The innate immune disorder market include Complement Deficiencies, Hyper IgE Syndrome and Others. Moreover this report also studies the global market by test for diagnosis which encompasses blood test and prenatal testing. The global PIDD market by treatment include both qualitative and quantitative analysis for immunoglobulin replacement therapy, antibiotics therapy, stem cell and gene therapy and others.

This exhaustive report includes a 360° view of the Primary Immunodeficiency Diseases Market. Browse through this 117-page report to know what factors will shape the market during the period 2015-2023

http://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html

Geographically the market is divided into four major regions: North America, Europe, Asia Pacific and Rest of the World. The North America market incorporates The United States and Canada. The Europe region is accessed for Germany, United Kingdom and Rest of Europe. The Asia Pacific (APAC) market is sub-segmented into India, China and Rest of APAC. Rest of the World (RoW) include Latin America, Middle East and North Africa and Rest of RoW

Each of the aforementioned segments has been analyzed in detail for market trends, recent developments, outlook, and opportunities. The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that currently have strong impact on the global PIDD market which could influence the market in the future as well. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition between leading market players in the U.S. market. Porter’s five forces analysis is also explained in this section to understand the market in U.S. considering different parameters that have an impact on the sustainability of the companies operating in the market.

The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their respective market shares across the globe. The recommendations section included in the report would assist existing market players in targeting the end users and stakeholders of PIDD and also to those aiming to seek an entry. The report also profiles major players in the PIDD market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Some of the leading companies operating in primary immunodeficiency diseases market across the globe. These encompasses Baxter International, Inc., Biotest AG, CSL Behring LLC, Bio Products Laboratory Ltd., Kedrion S.p.A., LFB S.A., Octapharma AG and Grifols S.A.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Primary Immunodeficiency Diseases Market during 2015- 2023

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: [email protected]

Website: http://www.transparencymarketresearch.com

#Primary Immunodeficiency Diseases Market Research Report: Forecast up to 2023

0 notes

itssashasharma · 3 years ago

Text

Autoinjectors Market worth USD 104.9 billion : Technological advancements in the field of Cardiovascular Diseases

According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular Diseases, Diabetes), Type (Disposable, Reusable), Route of administration (Subcutaneous, Intramuscular), End User (Hospital) – Global Forecast to 2025″, published by MarketsandMarkets™, the Autoinjectors Market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.

Browse in-depth TOC on “Autoinjectors Market”

99 – Tables 55 – Figures 180 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724

The Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

Diabetes segment is expected to show the highest growth in the forecast period.

The autoinjectors market, by therapy, is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, multiple sclerosis, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). Diabetes mellitus, commonly known as diabetes, is a disease that arises from the insufficient production of insulin or the body’s inability to utilize insulin. To maintain healthy blood glucose levels, diabetes patients need a daily intake of insulin or Glucagon-like peptide-1 (GLP-1). This scenario will provide companies with abundant opportunities to develop innovative solutions and cater the end user’s demand.

Disposable autoinjectors accounted for the largest share of the autoinjectors market in 2020.

Based on type, the market is segmented into reusable and disposable autoinjectors. In 2019, the disposable autoinjectors segment accounted for the largest share of the global market. Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need of manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairment.

Home care settings segment accounted for the largest share and is expected to show the highest growth in the forecast period.

Based on end users, the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. Of all these end-user segments, home care settings accounted for the largest share of the market in 2019. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724 Asia Pacific is expected to witness fastest growth during the forecast period of 2020–2025.

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is driven majorly by the large diabetes population and increasing healthcare expenditure in the regional countries have drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies

The prominent players in this market are AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

Browse Related Reports:

Pen Needles Market by Type (Standard Pen Needles and Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) – Global Forecast to 2024 https://www.marketsandmarkets.com/Market-Reports/pen-needles-market-75948613.html

Wearable Injectors Market by Type (On-Body and Off-Body injectors (Infusion Pump Devices)), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases, Parkinson’s disease, Thalassemia, Primary Immunodeficiency Disease) – Global Forecast to 2023 https://www.marketsandmarkets.com/Market-Reports/wearable-injector-market-100771004.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’ flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/autoinjector-market.asp Visit Our Web Site: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/autoinjector.asp

#Autoinjectors Market

0 notes

rohinic123-blog · 4 years ago

Text

Gene Therapy Market to Expand with Significant CAGR by 2026

Transparency Market Research (TMR) has published a new report titled, “Gene Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global gene therapy market was valued at US$ 17.0 Mn in 2017 and is projected to expand at a CAGR of 40.0% from 2018 to 2026. New product approvals, promising therapeutic outcomes of gene therapy, and high prevalence of non-Hodgkin Lymphoma are anticipated to drive the global market in the next few years. Europe is projected to dominate the global gene therapy market, followed by U.S., by the end of 2026. Potential unmet needs in the fields of oncology, rare genetic disorders in the U.S. and Europe, new product approvals and commercialization, and high clinical R&D budgets are likely to drive the gene therapy market in these regions during the forecast period. The gene therapy market in Rest of World is projected to expand at a significant CAGR during the forecast period. The high growth rate is attributed to the anticipated approval and commercialization of gene therapy products in developed countries such as Japan, Australia & New Zealand, GCC countries, and China, and high prevalence of non-Hodgkin Lymphoma and head and neck cancers.

Planning To Lay Down Future Strategy? Request Brochure Of Gene Therapy Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1838

New product approvals & commercialization drives market

2016, 2017, and 2018 were key milestones in the history of the gene therapy market in the U.S. and Europe, as around four gene therapy products have been approved and commercialized. These products are currently in the infancy stage of commercialization, and have exhibited highly positive therapeutic outcomes. For instance, in May 2016, GlaxoSmithKline (GSK) gene therapy product, Strimvelis, received marketing approval for the treatment of patients with a very rare disease called ADA-SCID (Severe Combined Immunodeficiency, due to Adenosine Deaminase deficiency). Strimvelis is the first ex-vivo stem cell gene therapy to be approved in Europe for the treatment of ADA-SCID. Furthermore, in August 2017, the USFDA approved Novartis AG’s flagship gene therapy product, Kymriah, for the treatment of children and adults up to the age of 25 years affected with B-cell precursor acute lymphoblastic leukemia (ALL). Thus, recent approvals of gene therapy products in the U.S. and Europe for the treatment of various life threatening disorders is projected to fuel the gene therapy market during the forecast period.

To Obtain All-Inclusive Information On Forecast Analysis Of Gene Therapy Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1838

Yescarta to be highest revenue generating gene therapy product

The report offers a detailed segmentation of the global gene therapy market based on different gene therapy products approved and commercialized. Based on product, the global gene therapy market has been segmented into Yescarta, Kymriah, Luxturna, Strimvelis, and Gendicine. Yescarta (Axicabtagene Ciloleucel) is a genetically modified autologous Chimeric Antigen Receptor T (CAR T) cell immunotherapy developed by Gilead Sciences, Inc. for the treatment of adult patients with relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). It is the first CAR T therapy approved by the US FDA for the treatment of DLBCL. The Yescarta segment is projected to dominate the global gene therapy market by the end of 2026. Anticipated commercialization of Yescarta in Europe and other developed countries and increasing number of treatment centers are key factors that are likely to lead to the dominant share held by Yescarta by the end of 2026.

Request For Covid19 Impact Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1838

Oncology segment to account for high market share

In terms of application, the global gene therapy market has been segmented into ophthalmology, oncology, and adenosine deaminase ?deficient severe combined immunodeficiency (ADA-SCID). The oncology segment is likely to account for a significant share of the market by the end of 2026. Oncology is a highly studied medical field in the clinical pipeline studies of gene therapy candidates. More than 60% of gene therapy clinical research studies are focused on oncology. The large share held by the oncology segment is attributed to the approval and commercialization of Yescarta and Kymriah, in the last one to two years, for the treatment of certain types of non-Hodgkin lymphoma in the U.S. and Europe. Furthermore, increase in demand for Gendicine in China for the treatment of head and neck cancers is projected to drive the segment during the forecast period.

Europe offers high incremental opportunity

The gene therapy market in Europe is projected to expand at a significant CAGR of 30.6% during the forecast period. Large number of patient population with refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), promising therapeutic outcomes, rising demand for gene therapy treatment, and increasing number of gene therapy treatment centers in Europe are key factors that are likely to fuel the gene therapy market in Europe. Moreover, different pricing models are being evaluated by payers and governments to enable access to high priced gene therapy products. This is likely to drive the demand for gene therapy products in Europe during the forecast period.

Large number of clinical pipeline studies and significant investments in gene therapy to gain the first mover advantage

The global gene therapy market is highly consolidated, with very few global players accounting for a major share. Currently, only five companies; Gilead life Sciences Inc. Spark Therapeutic Inc., Novartis AG, Sibiono GeneTech Co. Ltd, and Orchard Therapeutics Limited offer gene therapy products in the market. Most biopharmaceutical companies have invested significantly in clinical R&D for the development of gene therapy products for different chronic and genetic disorders. Large number of gene therapy products are under different stages of clinical pipeline studies, and the number of gene therapy candidates is projected to rise consistently during the forecast period. For instance, according to the Journal of Gene Medicine, there were around 2,597 gene therapy candidates under clinical trials, as of 2017. Of the total clinical studies, around 65% of studies were focused on oncology, 11% of studies were focused on monogenetic field, 7% on infectious diseases and cardiovascular disease, each.

More Trending Reports by Transparency Market Research –

Life Sciences BPO Market -

https://www.prnewswire.com/news-releases/life-sciences-bpo-market-is-expected-to-touch-us286-3-billion-by-2023--says-tmr-300813081.html

Read our Case study at

https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

0 notes

nita-world · 5 years ago

Text

Intravenous Immunoglobulin (IVIg) market Overview 2019 By Manufactures and Product scope

Intravenous Immunoglobulin (IVIg), a compound comprising of immune proteins (globulins) is administered into the bloodstream to treat patients with inefficient or damaged immune systems. IVIg provides the required antibodies by the human body to fight out the immune deficiency, and the ensuing infectious attacks.

Immunodeficiency disorder could be a hereditary issue (Primary disorders), or caused due to the exposure to infections, mainly through bodily fluids, along with the cancer drugs and chemotherapy, aging is one of the key risk factors too that could put someone at higher risk of a damaged immune system.

People nowadays are increasingly adopting heady & unhealthy lifestyles which mirror the prevalence of damaged immune system. Factors such as immense stress, lack of good quality sleep, inadequate & improper diet and sedentary lifestyle are fuelling the prevalence of immunodeficiency disorder and therefore, predominantly driving the growth of the market.

Considering the kind of the growth the market perceives currently; Market Research Future (MRFR) has recently published a study report giving out the complete market forecast up to 2023. In its analysis, MRFR asserts that the global intravenous immunoglobulin market growing further will reach USD 8337.2 MN by 2023, registering approximately 5.9% CAGR from 2017 to 2023.

The augmenting demand for alternate immunoglobulin replacement therapies, increasing R&D funding, rapidly developing healthcare infrastructure and increasing healthcare expenditures are major driving forces for the market growth. Technological advancements transpired in medical science, are fostering the growth of the market exponentially, bringing up new treatment procedures, & medications in the field of IVIg.

Additionally, factors such as growing population and geriatric populace worldwide are fostering market growth. Rapidly developing economy worldwide is providing impetus to the market growth, enabling access to the quality life & improved healthcare. Substantial investments made in the development of IVIg, by the key market players are paying off well, driving the growth of the market.

On the flip side, factors such as low awareness among people about the availability of treatment, the high cost of IVIg management along with the skepticism towards the advancement & efficacies of these treatments among the patients are likely to impede the growth of the Intravenous Immunoglobulin market.

Global Intravenous Immunoglobulin Market – Competitive Landscape

Fiercely competitive, the global IVIg market appears to be fragmented due to the presence of several large and small players. These players acquire small yet promising companies to expand their reach in the emerging markets, focusing on improving their market performance. The acquisition of local manufactures by multinational companies makes the market structure look dynamic. Strategies such as product innovations and technologies are creating strong investment opportunities for the players.

Major Players:

Key players leading the global IVIg market include Baxter (US), BDI Pharma (US), Abeona Therapeutics (US), China Biologic Products, Inc. (China), Grifols Inc. (Spain), Biotest AG. (Germany), CSL Behring (US), Octapharma (Switzerland), Kedrion S.p.A (US), and Shire (Republic of Ireland) among others.

Industry, Innovation & Related News

March 28, 2019 --- CSL Behring (the US), a leading global biotherapeutics and biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products announced the receiving of an approval from Japan's Ministry of Health, Labour and Welfare has for two of its immunoglobulin therapies - named Hizentra and Privigen for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Out of these, Hizentra which was previously approved for the treatment of primary immunodeficiency (PI) is now Japan's first and only subcutaneous immunoglobulin (SCIG) treatment approved for maintenance therapy to treat CIDP. Privigen, an intravenous immunoglobulin (IVIG), is now approved for both acute and maintenance treatment of CIDP in Japan.

Intravenous Immunoglobulin (IVIg) Market information, by type (IgA, IgD, IgE, IgG, IgM), by Appliaction (Chronic inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia, Multifocal Motor Neuropathy, Immunodeficiency diseases, Primary Humoral Immunodeficiency, Myasthenia Gravis, Guillain-Barre syndrome, Kawasaki disease, ITP, and others) - Forecast to 2023: https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137

0 notes

cool-dangerousheartcollecto-blog · 5 years ago

Text

According to New Market Report Blood Plasma Derivatives Market is to Witness Highest Growth in near future Forecast 2016-2023

A fresh report titled “Blood Plasma Derivatives Market” has been presented by KD market insights. It evaluates the key market trends, advantages, and factors that are pushing the overall growth of the market. The report also analyzes the different segments along with major geographies that have more demand for Blood Plasma Derivatives Market. The competition analysis is also a major part of the report.

Blood plasma is liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains the blood pressure and helps in exchange of important minerals such as sodium and potassium to maintain the pH balance in the body. Plasma derivatives are products that are manufactured from human plasma by plasma fractionation techniques. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.

Request for Sample @ https://www.kdmarketinsights.com/sample/3929

The global blood plasma derivatives market was valued at $23,613 million in 2016, and is projected to reach $44,333 million at a CAGR of 9.3% from 2017 to 2023. The major factor that contributes towards the growth of the blood plasma derivatives market is increase in prevalence of life-threatening diseases such as immunodeficiency disorders and hemophilia. Moreover, other factors boosting the market growth include increase in awareness for blood & plasma donation, rise in geriatric population, and high adoption of blood plasma derivatives products. However, high cost of treatment and risks of side effects associated with the use of plasma derivatives hamper the market growth. Conversely, development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market.

The global blood plasma derivatives market is segmented on the basis of type, application, end user, and region. Based on type, the market is fragmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The applications covered in the study include hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand’s Disease (vWD), and other application. By end user, the market is classified into hospitals, clinics, and other end users. Region wise, it is analyzed for North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

- The study provides an in-depth analysis of the global blood plasma derivatives market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.

- Comprehensive analysis of factors that drive and restrict the market growth is provided.

- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.

- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Key market segments

By Type

- Albumin

- Factor VIII

- Factor IX

- Immunoglobulin

- Hyperimmune Globulin

- Others

By Application

- Hemophilia

- Hypogammaglobulinemia

- Immunodeficiency Diseases

- von Willebrand’s disease (vWD)

- Other Application

By End User

- Hospitals

- Clinics

- Other End Users

By Region

North America

- U.S.

- Canada

- Mexico

Europe

- Germany

- France

- UK

- Italy

- Spain

- Rest of Europe

Asia-Pacific

- China

- Japan

- India

- Australia

- South Korea

- Rest of Asia-Pacific

LAMEA

- Brazil

- Saudi Arabia

- South Africa

- Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

- Grifols, S.A.

- SK Plasma Co., Ltd.

- Fusion Health Care Pvt. Ltd.

- Biotest AG

- Green Cross Corporation

- Baxter International Inc.

- LFB S.A.

- Octapharma AG

- CSL Limited

- Shire Plc.

Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/blood-plasma-derivatives-market-amr

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report description 1.2. Key benefits for stakeholders 1.3. Key market segments

1.3.1. By Type 1.3.2. By Application 1.3.3. By End User 1.3.4. By Region 1.3.5. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope 3.2. Key findings

3.2.1. Top investment pockets 3.2.2. Top winning strategies

3.3. Top player positioning 3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. High prevalence of life threatening diseases 3.4.1.2. Growth in awareness about blood and plasma donation 3.4.1.3. Rise in geriatric population 3.4.1.4. High adoption of blood plasma derivatives

3.4.2. Restraints

3.4.2.1. High cost of blood plasma derivatives based therapy 3.4.2.2. Risks associated with plasma derivatives

3.4.3. Opportunities

3.4.3.1. Development of better methods for plasma derivatives manufacturing 3.4.3.2. Opportunities in emerging economies

3.4.4. Impact analyses

3.5. Government regulations

3.5.1. Plasma derivatives regulations in United States and Europe

CHAPTER 4: BLOOD PLASMA DERIVATIVES MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Albumin

4.2.1. Key market trends, growth factors and opportunities 4.2.2. Market size and forecast, by region 4.2.3. Market analysis, by country

4.3. Factor VIII

4.3.1. Key market trends, growth factors and opportunities 4.3.2. Market size and forecast, by region 4.3.3. Market analysis, by country

4.4. Factor IX

4.4.1. Key market trends, growth factors and opportunities 4.4.2. Market size and forecast, by region 4.4.3. Market analysis, by country

4.5. Immunoglobulin

4.5.1. Key market trends, growth factors and opportunities 4.5.2. Market size and forecast, by region 4.5.3. Market analysis, by country

4.6. Hyperimmune globulin

4.6.1. Key market trends, growth factors and opportunities 4.6.2. Market size and forecast, by region 4.6.3. Market analysis, by country

4.7. Others

4.7.1. Key market trends, growth factors and opportunities 4.7.2. Market size and forecast, by region 4.7.3. Market analysis, by country

Continue…

Check for Discount @ https://www.kdmarketinsights.com/discount/3929

About KD Market Insights

KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights.

Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.

KD Market Insights

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email: [email protected]

Website: www.kdmarketinsights.com

Read More News: https://marketnewsbizz.com https://marketresearchtab.com https://kdmarketinsightsblog.com

#Blood Plasma Derivatives Market #Blood Plasma Derivatives Market Size #Blood Plasma Derivatives Market Share #Blood Plasma Derivatives Market Trends

0 notes

megasddw-blog · 6 years ago

Text

New Study 2019-2023 Global Stem Cell Therapy Industry Trend and Forecast Report

Complete Study of Global Stem Cell Therapy Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the Global Stem Cell Therapy Market.

Stem Cell Therapy Market - Analysis

Global Stem Cell Therapy Market is likely to touch at 10.3% CAGR during the forecast period. Stem-cell therapy simply put is the utilization of stem cells for preventing or treating a condition or disease. For over 55 years, stem cells have been used for treating serious diseases including cancer, dementia, type 1 diabetes, arthritis, stroke, heart disease, Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease, spinal cord injuries, burns and osteoarthritis. The stem cells are generally undifferentiated cells which are differentiated into the specialized cell types. There are a couple of key factors that is responsible for the massive growth of the global stem cell therapy market. These include new developments in the banking infrastructure of stem cells, increasing research in new stem cell line identification, rising public-private investment in stem cell research, development of latest genetic analysis techniques, increasing research for application of stem cell therapy and the increasing awareness for stem cells therapeutic application in disease management.

Stem cells are used for treating Alzheimer’s disease by using stem cells in place of the diseased cells. This method has an excellent potential to halt or prevent different forms of neurodegenerative diseases. More than 5.7 million Americans were diagnosed with Alzheimer’s disease as reported by the Alzheimer’s Association in 2018.

Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/6422

It is the increasing government funding and rising number of neurological diseases that has boost up the stem cell therapy market. But there are some factors however that may restrict the growth of the market during the forecast period. These include regulatory complications, lack of skilled labor exclusive procedures, cross contaminations and difficulty of collection as well as storage techniques of the somatic stem cells.

Stem Cell Therapy Market - Key Players

The leading players profiled in the report include Thermo Fisher Scientific Inc, AlloSource (US), RTI Surgical Inc (US), NuVasive Inc (US), JCR Pharmaceuticals Co. Ltd (Japan), HolostemTerapieAvanzateS.r.l. (Italy), Pharmicell Co., Ltd (South Korea), Anterogen Co., Ltd (South Korea), MEDIPOST Co., Ltd (South Korea), and Orisis Therapeutics, Inc. (US).

Latest research in September, 2018 jointly led by University of Pennsylvania and Fourth Military Medicine University revealed that stem cells from baby teeth can be harvested which will have prospective dental uses to repair and regenerate tissues and regrow the adult teeth without the need for dentures or crowns.

Stem Cell Therapy Market - Segmentation

In MFRF’s report, the global stem cell therapy market is segmented on the basis of type, therapeutic application, cell source and end-user.

On the basis of type, it is segmented into autologous and allogeneic. The latter had the largest market share in 2016 for a couple of reasons such as growing commercialization of allogeneic products, its higher therapeutic applications and rising clinical trials associated to this therapy.

On the basis of therapeutic application, it is segmented into diabetes, immunodeficiency, cancer, metabolic disorders, hematopoietic disorders, treatment of eyes, wound healing, neurodegenerative disorders, bone regeneration, cardiovascular disease and medicine.

On the basis of cell source, it is segmented into iPSCs, cord/embryo blood-derived, neural, bone marrow and adipose tissue.

On the basis of end-user, the stem cell therapy market is segmented into stem cell banks, contract research organizations, research institutes, hospitals and biotechnology companies.

Stem Cell Therapy Market - Regional Analysis

Based on region, the stem cell therapy market segmented into the Americas, Europe, Asia-Pacific and the Middle East and Africa. The Americas lead the market on account of factors such as growing healthcare expenditure and existence of heart diseases. After the Americas, Europe (Netherlands, France, Belgium and UK) grabs the second position. This can be attributed to factors such as the rising occurrence of osteoarthritis, cancer and stroke.

It is the Asia-Pacific which is the fastest growing region in this market and is likely to see further growth due to the increasing existence of smoking here. The Middle East & Africa (MEA) region holds a relatively smaller share of market due to lack of well-trained healthcare experts and low per capita income. However, both the increasing technology and oncology in the community and the hospital level are likely to positively influence the stem cell therapy market.

Browse Complete 90 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/stem-cell-therapy-market-6422

Some Points from TOC of Stem Cell Therapy Market Research Report – Forecast to 2023:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

TOC CONTINUED…

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: [email protected]

0 notes

sophiajhon-blog · 6 years ago

Text

Global Intravenous Immunoglobulin (IVIG) Market is Bost at a CAGR 7.5 % During 2018-2025

KD Market Insights has published a research report about Global Intravenous Immunoglobulin (IVIG) market that envisions boost for this market with 7.5 % CAGR (Compound Annual Growth Rate) for this market between 2018 and 2023. In terms of value, the market that is worth the USD $8,995 Million in 2017 is expected to be worth the USD $15,964 Million in 2025. The market research report demonstrates market dynamics which includes growth drivers, restraining factors and opportunities and trends spearheading current nature and future status of this market. In addition to this, the report includes market size, Y-O-Y growth analysis and structure of the overall industry based on a unique combination of industry research, fieldwork, market sizing analysis, and our in-house expertise. Our general approach is to target several individuals with specific questions that we believed would satisfy our research objective. Further, to speed up the data collection process, we employed an online survey, delivered via email. Also, the research team analysed the results to identify potential opportunities and risks for the market. Request for Sample @ https://www.kdmarketinsights.com/sample/3385 Segmentation By Application - Hypogammaglobulinemia - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Primary Immunodeficiency Disease - Myasthenia Gravis - Multifocal Motor Neuropathy - Idiopathic Thrombocytopenic Purpura (ITP) - Inflammatory Myopathies - Specific Antibody Deficiency - Guillainâ€“Barre Syndrome - Others By Type - IgG - IgA - IgM - IgE - IgD Regional Outlook. The report analyses the market by geographies i.e. North America, Europe, Asia Pacific, Latin America & Middle East & Africa. Further, the geographies are fragmented into the country and regional groupings: - North America (U.S. & Canada) - Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe) - Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific) - Latin America (Brazil, Mexico, Argentina and Rest of Latin America) - Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa) Competitive Landscape: The competitive landscape analysis provides detailed strategic analysis of the company’s business and performance such as financial information, revenue breakup by segment and by geography, SWOT Analysis, key facts, company overview, business strategy, key product offerings, marketing and distribution strategies, new product development, recent news (acquisition, expansion, technology development, research & development and other market activities). The study also provides company’s positioning and market share in Intravenous Immunoglobulin (IVIG) market. Competitive Landscape: - Baxter international Inc. - CSL Ltd. - Grifols, S.A. - Octapharma AG - Kedrion Biopharma Inc. - LFB Group - Biotest AG - China Biologics Products, Inc. - Takeda Pharmaceuticals - Bayer AG Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/intravenous-immunoglobulin-market-amr Table of Content CHAPTER 1: INTRODUCTION 1.1. Report description 1.2. Key benefits for stakeholders 1.3. Key market segments 1.4. Research methodology 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models CHAPTER 2: EXECUTIVE SUMMARY 2.1. CXO perspective CHAPTER 3: MARKET OVERVIEW 3.1. Market definition and scope 3.2. Overview of Immunoglobulin 3.2.1. Patented products 3.2.2. Epidemiology and economic burden of chronic conditions 3.3. Key findings 3.3.1. Top Investment Pockets 3.4. Porters five forces analysis 3.5. Value chain analysis 3.5.1. Primary activities 3.5.2. Support activities 3.6. Market share analysis, 2017 3.7. Product scenario in intravenous immunoglobulin market 3.8. Government regulations and reimbursements 3.8.1. U.S. 3.8.2. Europe 3.8.3. France 3.8.4. Germany 3.8.5. Italy 3.8.6. China 3.8.7. Japan 3.8.8. India 3.9. Indications for immunoglobulin 3.9.1. U.S. FDA indications 3.9.2. EMA 3.10. Component analysis of immunoglobulin G (IgG) 3.10.1. IgG1 3.10.2. IgG2 3.10.3. IgG3 3.10.4. IgG4 3.11. Market dynamics 3.11.1. Drivers 3.11.1.1. Rise in prevalence of immunodeficiency diseases 3.11.1.2. Increase in adoption of immunoglobulin treatment 3.11.1.3. Growth in incidence of bleeding disorders 3.11.2. Restraints 3.11.2.1. Stringent government regulations 3.11.2.2. High cost of therapy 3.11.3. Opportunities 3.11.3.1. Opportunities in emerging economies 3.11.3.2. Development of cost-effective therapeutics through large-scale production CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION 4.1. Overview 4.1.1. Market size and forecast 4.2. Hypogammaglobulinemia 4.2.1. Market size and forecast 4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP) 4.3.1. Market size and forecast 4.4. Primary immunodeficiency diseases 4.4.1. Market size and forecast 4.5. Myasthenia Gravis 4.5.1. Market size and forecast 4.6. Multifocal motor neuropathy 4.6.1. Market size and forecast 4.7. Idiopathic thrombocytopenic purpura (ITP) 4.7.1. Market size and forecast 4.8. Inflammatory myopathies 4.8.1. Market size and forecast 4.9. Specific antibody deficiency 4.9.1. Market size and forecast 4.10. Guillain-Barre syndrome 4.10.1. Market size and forecast 4.11. Others 4.11.1. Market size and forecast CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT 5.1. Overview 5.1.1. IGG 5.1.1.1. Key market trends 5.1.2. Clinical interpretations 5.1.3. IGA 5.1.3.1. Key Market Trends 5.1.4. Clinical interpretation 5.1.5. IGM 5.1.5.1. Key Market Trends 5.1.6. Clinical interpretation 5.1.7. IGE 5.1.7.1. Key Market Trend 5.1.8. Clinical interpretation 5.1.9. IGD 5.1.9.1. Key Market Trends 5.1.10. Clinical interpretation CHAPTER 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION 6.1. Overview 6.1.1. Market size and forecast 6.2. North America 6.2.1. Key trends and opportunities 6.2.2. North America market size & forecast, by application 6.2.3. North America market size & forecast, by country 6.2.3.1. U.S. market size & forecast 6.2.3.2. Canada market size & forecast 6.2.3.3. Mexico market size & forecast Continue…. Check for Discount @ https://www.kdmarketinsights.com/discount/3385 About Us: KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market. Contact Us: KD Market Insights 150 State Street, Albany, New York, USA 12207 +1 (518) 300-1215 Email: [email protected] Website: www.kdmarketinsights.com

#Intravenous Immunoglobulin Market #Intravenous Immunoglobulin Market size #Intravenous Immunoglobulin Market share #Intravenous Immunoglobulin Market news

0 notes

healthy-insights · 7 years ago

Text

Primary Immunodeficiency Diseases Market Research Report: Forecast up to 2023

Primary Immunodeficiency Diseases Market: Key Insights

In response to the rising incidence of antibody diseases, Transparency Market Research (TMR) forecasts the global primary immunodeficiency market to surge at 6.1% CAGR between 2015 and 2023. Developed regions such as Europe and North America are predominantly contributing to the growth witnessed by this market. The consistent approval of novel therapeutic options for primary immunodeficiency diseases (PIDD) and extensive research and development investments by key players are likely to bolster opportunities for the market in the forthcoming years.

On the flip side, the absence of proper reimbursement and high cost of therapies will inhibit the market’s growth trajectory to an extent. Nevertheless, with favorable government policies and funding for research and development in biopharma and pharmaceuticals, growth prospects for the market seem quite promising.

TMR expects the global PIDD market to reach US$7.5 bn by the end of 2023, from a valuation of US$4.3 bn in 2014.

This exhaustive report includes 360° view of the Primary Immunodeficiency Diseases Market. Browse through this 117-page report to know what factors will shape the market during the period 2015-2023

http://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html

Demand for PIDD Treatment Highest in North America and Europe

Collectively accounting for a share of 79.4% in the global PIDD market, North America and Europe emerged as the dominant regional segments in 2014. Among these regions, North America boasted the largest share of 56.2% in 2014, with the U.S. at the fore. As per TMR, the U.S. held over 80.2% of the PIDD market in North America in the same year. The nation is expected to continue demonstrating lucrative opportunities for the PIDD market through the forecast period.

Over the last couple of years, a persistently increasing prevalence of diseases such as selective IgA deficiency, IgG subclass deficiency, and common variable immune deficiency has been witnessed in North America. This has fuelled the uptake of PIDD therapeutics. However, the growing awareness pertaining to side-effects such as renal failure and allergic reactions frequently associated with the treatment could hamper the market’s growth to an extent.

The primary immunodeficiency diseases market in North America, which stood at US$2.4 bn in 2014, is expected to reach US$4.3 bn by the end of 2023. The market is therefore expected to rise at a CAGR of 6.4% during the period.

In Europe, the market is expected to gain from the increasing awareness regarding PIDD and favorable government support. The presence of companies such as Baxter International Inc., CSL Behring LLC, and Blotest Pharmaceuticals Corporation also supports the market’s expansion in the region. Apart from this, emerging nations in Asia Pacific also exhibit lucrative scope for the expansion of the PIDD market. The increasing willingness among people to spend on novel therapeutics augurs well for sales prospects of the market in Asia Pacific. The region currently holds only a moderate share in the market. However, in the near future the opportunities for sale of PIDD therapeutics in the region will increase considerably.

Rising Uptake of Immunoglobulin (Ig) Replacement Therapy Expected in Near Future

By treatment, stem cell and gene therapy, antibiotic therapy, immunoglobulin (Ig) replacement therapy, and others make the key segments in the global PIDD market. Of these, immunoglobulin replacement has been in use for the treatment of chronic ailments for the past two decades. Due to the recent developments, it is also used for the treatment of partial antibody deficiency and combined immunodeficiencies. The segment therefore emerged dominant in the market in 2014. As per TMR, immunoglobulin replacement therapy will hold on to its position as the market leader through the forecast period.

Despite, Ig replacement therapy being the most widely accepted treatment among PIDD patients, the use of antibiotics as an adjunct therapy is poised to surge in the near future. Some of the most commonly used antibiotics include penicillin, macrolides, cephalosporins, fluoroquinolones, and tetracyclines.

The demand for stem cell and gene therapy is also expected to increase during the forecast period, which in turn will augment the demand for effective PIDD treatment.

Some of the most prominent companies in the global primary immunodeficiency diseases market are CSL Behring LLC, Baxter International, Inc., Grifols S.A., Octapharma AG, and others.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Primary Immunodeficiency Diseases Market during 2015- 2023

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137

About Us

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: [email protected]

Website: http://www.transparencymarketresearch.com

#Primary Immunodeficiency Diseases Market Research Report: Forecast up to 2023

0 notes

healthy-insights · 8 years ago